Rhabdomyosarcoma News and Research

RSS

Both vaccine strain and adjuvant selection are critical elements for improving the breadth of protective immunity against enterovirus D68

Researchers demonstrated the production of cross-clade neutralizing antibodies in response to EV-D68.

19 May 2023

Scientists use enhanced environmental surveillance for poliovirus type 2 detection in London sewage samples

In a new study, researchers investigated molecular properties of type 2 poliovirus (PV) isolates obtained from sewage samples (SS) to detect PV transmission in communities.

17 Oct 2022

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

In a study recently published in Cancer Research, a journal of the American Association for Cancer Research, a team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director for the Texas Tech University Health Sciences Center School of Medicine Cancer Center, sought to expand upon his lab's previous research that showed ALT tumors identified by a biomarker known as C-circles share a common biology that confers vulnerabilities to be exploited for cancer therapy.

10 Aug 2022

New discovery may open the door to targeted treatments for two types of rhabdomyosarcoma

A gene that UVA Health researchers discovered is responsible for the deadliest type of brain tumor is also responsible for two forms of childhood cancer, the scientists have found.

28 Jul 2022

Phase I clinical trial of new blocking antibody therapy shows promising results for the treatment of advanced medulloblastoma

Effective and safe treatments are needed for medulloblastoma-;the most common type of cancerous brain tumor in children-;especially for patients whose cancer has spread to the spinal cord.

14 Jul 2022

Improving Patient Recruitment for Clinical Trial Research

In this interview, we speak to Matt Walz, CEO of Trialbee, about the importance of improving patient recruitment and retention within clinical trials.

From Trialbee 23 May 2022

Researchers Identify Potential Target for Rhabdomyosarcoma Recurrence Prevention

In this interview, News-Medical speaks to Anand Patel and Michael Dyer from St. Jude's Children's Research Hospital about their recent research suggesting EGFR inhibitors may prevent rhabdomyosarcoma recurrence.

12 May 2022

Research reveals a therapeutic opportunity to prevent rhabdomyosarcoma recurrence

Rhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.

27 Apr 2022

Soy molasses and kudzu roots may help fight against pediatric tumors

Soy molasses and kudzu roots contain isoflavonoids with high antioxidant and cytotoxic activity, scientists have discovered.

30 Mar 2022

TTUHSC researcher secures $1.9 million grant to investigate vulnerabilities in ALT cancers

The National Cancer Institute, part of the National Institutes of Health, recently awarded a five-year, $ $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at the Texas Tech University Health Sciences Center.

23 Mar 2022

Research reveals a possible new treatment approach for pediatric rhabdomyosarcoma

Scientists at St. Jude Children's Research Hospital have revealed how the tumor suppressor gene PTEN plays a more important role in pediatric rhabdomyosarcoma than was previously appreciated.

18 Sep 2021

New findings shed light on genetic changes that underlie rare, aggressive childhood cancer

A new study could lead to improved decision making in assigning treatments for children with the aggressive cancer rhabdomyosarcoma after revealing key genetic changes underlying development of the disease.

24 Jun 2021

Study findings help explain the diversity of cancers in different Li-Fraumeni patients

The most frequently mutated gene in human cancers is called p53. Patients with Li-Fraumeni syndrome, which is a rare disorder that increases the risk of developing several types of cancer, often have an increased risk to develop cancers at early ages if they inherit p53 mutations.

23 Feb 2021

MFCR awards new grants to support an emerging approach to cancer therapeutics

The Mark Foundation for Cancer Research has awarded five new grants in support of an important, emerging approach to cancer therapeutics.

17 Dec 2020

Genomic analysis of neuroblastoma sheds light on childhood solid tumors

Researchers have used insight from a comprehensive genomic analysis of neuroblastoma to learn about the process driving one of the most common childhood solid tumors. The findings revealed possible approaches for developing precision medicines to improve patient outcomes. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Nature Communications.

15 Oct 2020

Two young scientists receive Damon Runyon-Sohn Pediatric Cancer Fellowship Award

The Damon Runyon Cancer Research Foundation has named two outstanding young scientists as recipients of the Damon Runyon-Sohn Pediatric Cancer Fellowship Award, committing nearly $500,000 to help address a critical shortage of funding for pediatric cancer research.

30 Jul 2020

Promising new CAR T cell therapy results in exceptional patient recovery

In a clinical trial evaluating a novel immunotherapy option for cancer treatment, a child with rhabdomyosarcoma, a form of muscle cancer, that had spread to the bone marrow, showed no detectable cancer following treatment with chimeric antigen receptor (CAR) T cells that were engineered to target the HER2 protein on the surface of the cancer cells.

15 Jul 2020